{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:59Z","timestamp":1761178559205,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.canrad.2020.06.026","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:20:10Z","timestamp":1614990010000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The safety and efficacy of Cyberknife\u00ae for thymic malignancy"],"prefix":"10.1016","volume":"25","author":[{"given":"C.","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2020.06.026_bib0195","first-page":"S259","article-title":"Proceedings of the first International conference on thymic malignancies. August 20\u201321, 2009. Bethesda, Maryland, USA","volume":"5","author":"Giuseppe Giaccone","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0200","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/ejcts\/ezv288","article-title":"Surgical treatment of thymoma: an 11-year experience with 761 patients","volume":"49","author":"Zhao","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jtcvs.2009.03.033","article-title":"Comparison of patterns of relapse in thymic carcinoma and thymoma","volume":"138","author":"Huang","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0210","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0215","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/JTO.0000000000000363","article-title":"Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging","volume":"9","author":"Litvak","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0220","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumours: a clinical study of 1320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0225","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","article-title":"Thymic carcinoma: state of the art review","volume":"59","author":"Eng","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.06.026_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2003.09.022","article-title":"Multimodal management of stages III\u2013IVa malignant thymoma","volume":"44","author":"Bretti","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2020.06.026_bib0235","first-page":"161","article-title":"Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome","volume":"62","author":"Ried","year":"2014","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0240","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.athoracsur.2012.01.014","article-title":"Thymic carcinoma: outcomes after surgical resection","volume":"93","author":"Okereke","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2015.03.001","article-title":"Patterns and predictors of recurrence after radical resection of thymoma","volume":"115","author":"Xu","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0250","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.athoracsur.2008.11.022","article-title":"Adjuvant radiotherapy for thymic epithelial tumours: a systematic review and meta-analysis","volume":"87","author":"Korst","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0255","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.canrad.2007.09.146","article-title":"CyberKnife robotic stereotactic radiotherapy: technical aspects and medical indications","volume":"11","author":"Bondiau","year":"2007","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2020.06.026_bib0260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0971-6203.62194","article-title":"CyberKnife: a new paradigm in radiotherapy","volume":"35","author":"Kurup","year":"2010","journal-title":"J Med Phys"},{"key":"10.1016\/j.canrad.2020.06.026_bib0265","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1118\/1.3315370","article-title":"Direct tumour in vivo dosimetry in highly conformal radiotherapy: a feasibility study of implantable MOSFETs for hypofractionated extracranial treatments using the Cyberknife system","volume":"37","author":"Scalchi","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2020.06.026_bib0270","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1684\/bdc.2010.1141","article-title":"Cyberknife robotic stereotactic radiotherapy: technical aspects and recent developments","volume":"97","author":"Thariat","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1016\/j.canrad.2020.06.026_bib0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000099863","article-title":"The Cyberknife: a frameless robotic system for radiosurgery","volume":"69","author":"Adler","year":"1997","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0280","first-page":"ONS147","article-title":"A study of the accuracy of Cyberknife spinal radiosurgery using skeletal structure tracking","volume":"60","author":"Ho","year":"2007","journal-title":"Neurosurgery"},{"key":"10.1016\/j.canrad.2020.06.026_bib0285","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.06.026_bib0295","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0300","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jrr\/rrw028","article-title":"Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis\/inferior vena cava tumour thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy","volume":"57","author":"Matsuo","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.canrad.2020.06.026_bib0305","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/L15-0469","article-title":"Treatment of thymoma-associated myasthenia gravis with stereotactic body radiotherapy: a case report","volume":"165","author":"Lee","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.canrad.2020.06.026_bib0310","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.3747\/co.22.2693","article-title":"Stereotactic ablative radiotherapy with CyberKnife for advanced thymic carcinoma: a case report","volume":"22","author":"Fan","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0315","first-page":"e1056","article-title":"Thymic carcinoma treated by CyberKnife stereotactic body radiotherapy","volume":"9","author":"Harada","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.canrad.2020.06.026_bib0320","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1038\/s41598-017-12909-z","article-title":"Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment","volume":"7","author":"Hao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2020.06.026_bib0325","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1097\/JTO.0b013e3181f20f27","article-title":"Surgical treatment of recurrent thymomas","volume":"5","author":"Lucchi","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0330","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.athoracsur.2013.12.024","article-title":"Factors predicting recurrence and post-recurrence survival in completely resected thymic carcinoma","volume":"97","author":"Yen","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2020.06.026_bib0335","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/JTO.0000000000000370","article-title":"Long-term results after treatment for recurrent thymoma: a multicentre analysis","volume":"9","author":"Sandri","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0340","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2020.06.026_bib0345","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0167-8140(03)00003-3","article-title":"Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review","volume":"67","author":"Moiseenko","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0355","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1667\/RR3049","article-title":"Studies of mortality of atomic bomb survivors. Report 13: solid cancer and non-cancer disease mortality: 1950\u20131997","volume":"160","author":"Preston","year":"2003","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2020.06.026_bib0360","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2020.06.026_bib0365","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-17-2302","article-title":"AACR Cancer progress report 2017: harnessing research discoveries to save lives","volume":"23","author":"Tessmer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2020.06.026_bib0370","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0375","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumour: an open-label phase II trial","author":"Cho","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.026_bib0380","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832182030322X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832182030322X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:33:17Z","timestamp":1761136397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S127832182030322X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S127832182030322X"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2020.06.026","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of Cyberknife\u00ae for thymic malignancy","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2020.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}